# ATA-200 Gene Therapy Trial in Patients With LGMDR5

> **NCT05973630** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Atamyo Therapeutics** · enrollment: 4 (actual)

## Conditions studied

- LGMD2C

## Interventions

- **BIOLOGICAL:** ATA-200

## Key facts

- **NCT ID:** NCT05973630
- **Lead sponsor:** Atamyo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2026-10-30
- **Final completion:** 2031-01-31
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05973630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05973630, "ATA-200 Gene Therapy Trial in Patients With LGMDR5". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05973630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*